# Drug of interest
My drug of interest is Delamanid.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. CYP2D6 (z: 4.9)
2. CYP3A5 (z: 3.71)
3. CYP3A4 (z: 2.84)
4. ABCB1 (z: 2.56)
5. CYP2C19 (z: 2.12)
6. CYP2D7 (z: 1.56)
7. CYP2C9 (z: 0.99)
8. CYP2S1 (z: 0.98)
9. SLCO1B1 (z: 0.69)
10. CYP2C8 (z: 0.67)
11. CYP3A7 (z: 0.61)
12. CYP3A43 (z: 0.5)
13. ABCB4 (z: 0.46)
14. CYP2F1 (z: 0.41)
15. CYP2J2 (z: 0.39)
16. CYP2B6 (z: 0.38)
17. CYP2A13 (z: 0.36)
18. NR1I2 (z: 0.34)
19. ABCC2 (z: 0.33)
20. CYP2C18 (z: 0.32)
21. CYP2A7 (z: 0.32)
22. FMO5 (z: 0.31)
23. FMO4 (z: 0.24)
24. CYP24A1 (z: 0.23)
25. CYP2E1 (z: 0.2)
26. ABCG2 (z: 0.19)
27. SLCO1B3 (z: 0.17)
28. RUNDC3B (z: 0.17)
29. CYP4A11 (z: 0.12)
30. CYP4B1 (z: 0.11)
31. CYP26C1 (z: 0.11)
32. G6PD (z: 0.1)
33. CYP2A6 (z: 0.09)
34. SLCO5A1 (z: 0.09)
35. CYP7A1 (z: 0.08)
36. HLA-A (z: 0.08)
37. CYP2R1 (z: 0.07)
38. CYP4F11 (z: 0.07)
39. CYP4F12 (z: 0.07)
40. UGT1A1 (z: 0.06)
41. CYP4F2 (z: 0.06)
42. HLA-B (z: 0.06)
43. IFNL3 (z: 0.05)
44. CYP1B1 (z: 0.05)
45. CYP4F8 (z: 0.05)
46. POR (z: 0.05)
47. HLA-C (z: 0.05)
48. CYP21A2 (z: 0.05)
49. ZSCAN25 (z: 0.05)
50. PLGLB1 (z: 0.05)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**Delamanid**: Delamanid's metabolism in humans is predominantly governed by the CYP3A4 enzyme, with variations in the CYP3A4 gene affecting the drug's pharmacokinetics through altered enzyme activity, impacting its efficacy and safety. Additionally, genetic variations in the proteins albumin (ALB) and alpha-1-acid glycoprotein 1 (ORM1) might affect delamanid's distribution and half-life, while mutations in the mycobacterial enzyme required for activating delamanid can lead to drug resistance by altering enzyme efficiency.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.

**CYP3A7**: The CYP3A7 enzyme, important in fetal liver metabolism, interacts with drugs like atorvastatin and tacrolimus by potentially altering their pharmacokinetic profiles and systemic exposure during fetal development due to its activity in metabolizing these CYP3A substrates. Additionally, corticosteroids such as betamethasone and cortisone acetate may also interact with CYP3A7, affecting their metabolic rates and therapeutic outcomes in neonates and infants, though the specific pathway (pharmacokinetic or pharmacodynamic) of these interactions is less defined.

**CYP3A43**: The gene CYP3A43, although not a major player in drug metabolism compared to other enzymes in its subfamily, is known to have specific pharmacokinetic interactions with drugs like olanzapine and ticagrelor, influencing their clearance and plasma concentrations to a minor degree. Its interactions with other antipsychotic drugs such as quetiapine, haloperidol, aripiprazole, risperidone, and clozapine are less defined and are likely related to broader metabolic pathways or pharmacodynamic responses, where CYP3A43 plays a marginal role.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**CYP2B6**: CYP2B6 plays a pivotal role in the metabolism of several drugs, including efavirenz, nevirapine, methadone, bupropion, cyclophosphamide, and ifosfamide, where genetic polymorphisms can significantly influence drug efficacy and safety by altering pharmacokinetic profiles. Genetic variations in CYP2B6 affect the enzyme activity, leading to differences in drug plasma concentrations, therapeutic effects, and potential adverse reactions in individuals, underscoring its importance in personalized medicine.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**FMO5**: The FMO5 gene, unlike its family members, has a unique role in pharmacogenetics, particularly due to its broad substrate specificity and presence in the liver and small intestine. It indirectly influences drug metabolism, such as with metformin, by potentially altering the metabolic environment or modifying intermediate biomolecules, thus affecting the drug's efficacy and safety through non-traditional pathways related to its handling of metabolic byproducts connected to sulfur and nitrogen.

**FMO4**: The FMO4 gene encodes for the enzyme flavin-containing monooxygenase 4, which potentially contributes to the metabolism of drugs by affecting their pharmacokinetics, altering plasma drug levels, and impacting therapeutic outcomes or side effects. The exact drugs impacted by FMO4 are still speculative, as FMO4’s interactions with specific drugs are currently not well-documented and remain under research.

**CYP24A1**: The drugs telaprevir, deferasirox, and daclatasvir may interact with the CYP24A1 enzyme, which is crucial for metabolizing vitamin D, thereby potentially affecting the bioavailability of active vitamin D levels and altering drug metabolism. This understanding is important for predicting drug efficacy and safety, which may necessitate adjustments in dosage and treatment monitoring based on individual genetic variations in CYP24A1 activity.

**CYP2E1**: The gene CYP2E1 significantly impacts the metabolism of various drugs; for instance, in the case of acetaminophen and isoniazid, variations in CYP2E1 activity can lead to differences in the rate at which these drugs are metabolized, thereby affecting their efficacy, toxicity, and risk of adverse effects such as hepatotoxicity. Additionally, CYP2E1 metabolizes other substances like caffeine, theophylline, nicotine, and some procarcinogens, indicating that genetic variations could influence both therapeutic outcomes and disease risk through pharmacokinetic and possibly pharmacodynamic interactions.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**SLCO1B3**: SLCO1B3, which encodes the organic anion transporting polypeptide 1B3 (OATP1B3), plays a crucial role in the hepatic uptake and metabolism of several drugs including docetaxel, mycophenolate mofetil, telmisartan, and voriconazole, affecting their plasma levels, therapeutic effects, and toxicity. Variants in this gene can modify the transport efficiency of these drugs, influencing their absorption, distribution, elimination, and overall pharmacokinetics, thereby necessitating tailored dosing in personalized medicine to enhance efficacy and reduce adverse effects.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**CYP4A11**: CYP4A11, a gene involved in fatty acid metabolism, has potential pharmacogenetic implications in hypertension treatment, particularly through indirect interactions with potassium-sparing diuretics like spironolactone and amiloride. These interactions are speculated to involve modulation of hormonal pathways or ion transport mechanisms, rather than direct metabolism by the enzyme, affecting fluid and electrolyte balance critical for blood pressure regulation.

**CYP4B1**: CYP4B1, which is involved in the metabolism of fatty acids and xenobiotics, may potentially interact with drugs like docetaxel and thalidomide due to their structural similarities to fatty acids. This interaction could alter the pharmacokinetics of these drugs, affecting their efficacy and safety, although direct evidence of this is currently limited.

**CYP26C1**: CYP26C1, responsible for retinoic acid metabolism, affects the pharmacokinetics of retinoids like isotretinoin and acitretin, where its genetic variations can alter drug metabolism, influencing their efficacy and safety. Increased CYP26C1 activity might reduce the effectiveness of these drugs by speeding up their metabolism, while decreased activity could increase drug toxicity by allowing higher drug concentrations in the body, suggesting a need for personalized dosing based on CYP26C1 genotype.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**CYP2A6**: CYP2A6, an enzyme from the cytochrome P450 superfamily, influences the metabolism of various drugs, impacting their efficacy and toxicity due to genetic variations. It plays a critical role in metabolizing smoking cessation aids like nicotine, cancer treatments such as cyclophosphamide and tegafur, HIV treatment efavirenz, and the glaucoma drug pilocarpine, necessitating dosage adjustments or changes in drug choices to optimize outcomes and minimize side effects.

**SLCO5A1**: The SLCO5A1 gene, encoding a protein in the organic anion transporter family, is involved in the pharmacokinetics of drugs by influencing their absorption, distribution, metabolism, and excretion. Although specific drugs directly associated with SLCO5A1 have not been identified, it's suggested that drugs handled by similar OATP transporters, like statins, antivirals, and anticancer agents, might interact with SLCO5A1, thereby affecting their effectiveness and safety through altered absorption rates or bioavailability.

**CYP7A1**: CYP7A1, important for cholesterol and bile acid metabolism, influences the effectiveness of drugs like atorvastatin and cholic acid. The gene's activity can alter bile acid synthesis, thereby affecting atorvastatin's absorption and metabolism as well as the efficacy of cholic acid in treating bile acid synthesis disorders.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**CYP2R1**: Variations in the CYP2R1 gene can affect the efficiency of vitamin D metabolism by altering the enzyme's ability to convert vitamin D into 25-hydroxyvitamin D, influencing the effectiveness of vitamin D supplementation. Additionally, interactions between CYP2R1 and ribavirin don't involve direct metabolism by the enzyme but may involve indirect effects related to ribavirin’s impact on vitamin D levels or bone health, potentially affecting treatment outcomes in conditions like chronic hepatitis C.

**CYP4F11**: The enzyme CYP4F11 is involved in the metabolism of drugs such as warfarin, aspirin, and erlotinib, influencing their effectiveness and safety by altering degradation rates, plasma levels, therapeutic efficacy, and the profile of side effects. Variations in the activity of CYP4F11 can affect how these drugs are processed in the body, thereby potentially impacting dosage requirements and risk of adverse effects.

**CYP4F12**: CYP4F12, a cytochrome P450 enzyme, influences the metabolism of drugs that interact with lipid metabolism pathways, including NSAIDs, by affecting processes like hydroxylation of fatty acids. Variants in CYP4F12 could alter the pharmacokinetics of these drugs, potentially impacting their efficacy and safety.

**UGT1A1**: UGT1A1 plays a critical role in drug metabolism primarily through glucuronidation, affecting both pharmacokinetics and pharmacodynamics. For example, the gene’s variations, like UGT1A1*28, reduce the clearance of drugs such as irinotecan's active metabolite SN-38, leading to severe side effects and requiring dosage adjustments. Similarly, UGT1A1 influences the metabolism of HIV drugs like atazanavir and indinavir, impacting their effectiveness and concentration in the body. This gene also affects the metabolism of other medications such as atorvastatin, impacting treatments across various therapeutic areas like cancer and lipid management.

**CYP4F2**: CYP4F2 significantly influences the metabolism of drugs such as vitamin E, vitamin K1, warfarin, and acenocoumarol, affecting their bioavailability and dosing requirements. The enzyme's activity, particularly influenced by the V433M genetic variant, is crucial for the proper breakdown and clearance of these drugs, directly impacting their therapeutic levels and the potential for adverse effects.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**IFNL3**: Variants of the IFNL3 gene, such as rs12979860, significantly affect the treatment outcomes of hepatitis C, particularly with respect to pegylated interferon and ribavirin, where the CC genotype leads to better responses. Additionally, IFNL3 genetic variations influence the effectiveness of direct-acting antivirals like simeprevir and sofosbuvir, among others, by modulating the immune system's response to these medications, potentially impacting a broader range of antiviral treatments including those for HIV and HBV.

**CYP1B1**: CYP1B1 plays a crucial role in the metabolism of a variety of drugs, notably affecting the efficacy and toxicity of oncological treatments such as cyclophosphamide, docetaxel, doxorubicin, epirubicin, paclitaxel, and fluorouracil, and influencing the activation and effectiveness of pain management drugs like codeine and tramadol. Genetic polymorphisms in CYP1B1 can lead to altered enzyme activity, potentially necessitating dosage adjustments to optimize therapeutic outcomes and minimize side effects.

**CYP4F8**: CYP4F8 plays a role in the metabolism of fatty acids and leukotriene B4, suggesting that variations in this gene could influence the metabolism and efficacy of dermatological and anti-inflammatory drugs, particularly those like montelukast or zileuton that target leukotriene pathways. The interaction of CYP4F8 with these drugs primarily affects their pharmacokinetics, potentially altering drug effectiveness and safety.

**POR**: Genetic variations in the POR gene, which is crucial for the function of Cytochrome P450 Oxidoreductase, can significantly affect the pharmacokinetics of drugs such as bupropion, nicotine, tacrolimus, sirolimus, midazolam, voriconazole, and methadone by altering their metabolism and necessitating dose adjustments. While drugs like atorvastatin and sunitinib are also influenced by POR, their interaction is less directly related to its metabolic role, and other drugs such as aspirin and warfarin show complex pharmacodynamic interactions with POR-modulated enzymes rather than straightforward metabolic effects.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**CYP21A2**: The pharmacogenetic interactions of CYP21A2 focus on its role in managing congenital adrenal hyperplasia (CAH), where mutations in this gene affect enzyme activity crucial for steroid biosynthesis. This dictates the use of tailored glucocorticoid therapy, using drugs like hydrocortisone in children and prednisone or dexamethasone in adults, and fludrocortisone for aldosterone deficiency. Treatment adjustments—including the choice and dosage of medication—are essential based on specific CYP21A2 mutations to avoid negative effects such as growth suppression or insufficient control of androgen excess.

**ZSCAN25**: ZSCAN25 is hypothesized to interact with a diverse range of drugs including apixaban, finasteride, and simvastatin, among others, due to its role in transcriptional regulation which could impact pharmacodynamic processes. However, there is currently no direct evidence or mechanistic insights linking ZSCAN25 to specific pharmacodynamic or pharmacokinetic changes with these medications, making any such interactions speculative at this point.

**PLGLB1**: Although the PLGLB1 gene is structurally similar to plasminogen and is involved in the fibrinolytic system, there are no direct pharmacogenetic interactions documented with specific drugs, including thrombolytics like alteplase or streptokinase. The gene's influence on drug behavior, including drugs used in the management of myocardial infarction and stroke, remains speculative without clinical evidence linking PLGLB1 to the pharmacokinetics or pharmacodynamics of these drugs.
